Goldman Sachs Boosts RVMD to Buy with $267 Target Amid Biotech Resilience
Goldman Sachs has reinitiated its coverage of Revolution Medicines Inc (RVMD) with a Buy rating and a $267 price target. This decision reflects Goldman Sachs' renewed confidence in the biotechnology sector's resilience despite macroeconomic headwinds.
The firm's analysts emphasize the sector's strength, driven by strong acquisition activity, promising clinical trial results, and a more favorable regulatory landscape. Revolution Medicines specializes in developing targeted therapies for RAS-addicted cancers, with a pipeline centered on RAS(ON) inhibitors.
However, RVMD trades at a Price-to-Sales ratio far above its historical median (~70.8x) and industry norms, reflecting market expectations of significant future growth. Despite this, the company's unprofitable, cash-flow-negative status renders traditional earnings-based valuation metrics inapplicable.